Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Fridrik · SciRah

Researcher profile · Semantic Scholar

M. Fridrik

Share profile

M. Fridrik — researcher profile on SciRah

h-index: 22
Works: 133
Citations: 3,107

Most-cited papers

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
M. Gnant, B. Mlineritsch, W. Schippinger, G. Luschin-Ebengreuth +18 more
2009New England Journal of Medicine494 citations Open access
Semantic Scholar
Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.
R. Jakesz, H. Hausmaninger, E. Kubista, M. Gnant +11 more
2002Journal of Clinical Oncology290 citations
Semantic Scholar
Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group.
W. Fischbach, B. Dragosics, M. Kolve-Goebeler, C. Ohmann +46 more
2000Gastroenterology242 citations Open access
Semantic Scholar
Iron metabolism and iron supplementation in cancer patients
H. Ludwig, R. Evstatiev, G. Kornek, M. Aapro +13 more
2015Wiener Klinische Wochenschrift140 citations Open access
Semantic Scholar
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response
U. Jäger, M. Fridrik, M. Zeitlinger, D. Heintel +12 more
2012Haematologica110 citations Open access
Semantic Scholar
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study f
M. Fridrik, U. Jaeger, A. Petzer, W. Willenbacher +8 more
2016European Journal of Cancer76 citations
Semantic Scholar
Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four-year results of Austrian Breast Cancer Study Group (ABCSG) trial 5
R. Jakesz, H. Hausmaninger, H. Samonigg, E. Kubista +10 more
199976 citations
Semantic Scholar
Sentinel Node Biopsy Performed Before Preoperative Chemotherapy for Axillary Lymph Node Staging in Breast Cancer
P. Schrenk, G. Hochreiner, M. Fridrik, W. Wayand
2003The Breast Journal71 citations Open access
Semantic Scholar
Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
M. Schmid, R. Jakesz, H. Samonigg, E. Kubista +14 more
2003Journal of Clinical Oncology68 citations
Semantic Scholar
Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)
C. Tausch, S. Taucher, P. Dubsky, M. Seifert +8 more
2012Annals of Surgical Oncology59 citations
Semantic Scholar
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
B. von Tresckow, S. Kreissl, H. Goergen, P. Bröckelmann +11 more
2018The Lancet Haematology48 citations Open access
Semantic Scholar
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
R. Greil, P. Obrtlíková, L. Smolej, T. Kozák +31 more
2016The Lancet Haematology45 citations
Semantic Scholar
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)
B. Mlineritsch, C. Tausch, C. Singer, G. Luschin-Ebengreuth +12 more
2008Breast Cancer Research and Treatment42 citations
Semantic Scholar
Anemia Is a Significant Prognostic Factor in Local Relapse-Free Survival of Premenopausal Primary Breast Cancer Patients Receiving Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil Chemotherapy
P. Dubsky, P. Sevelda, R. Jakesz, H. Hausmaninger +15 more
2008Clinical Cancer Research41 citations Open access
Semantic Scholar
Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group.
Elisabeth Kucera, P. Speiser, M. Gnant, L. Szabó +9 more
1999European Journal of Cancer39 citations
Semantic Scholar
Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentöse Tumortherapie
M. Troch, B. Kiesewetter, W. Willenbacher, E. Willenbacher +6 more
2013Haematologica34 citations Open access
Semantic Scholar
Sentinel node mapping performed before preoperative chemotherapy may avoid axillary dissection in breast cancer patients with negative or micrometastatic sentinel nodes.
P. Schrenk, C. Tausch, S. Wölfl, S. Bogner +2 more
2008American Journal of Surgery31 citations
Semantic Scholar
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
R. Jakesz, H. Hausmaninger, K. Haider, E. Kubista +11 more
1999Journal of Clinical Oncology31 citations
Semantic Scholar
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
T. Kühr, S. Burgstaller, U. Apfelbeck, W. Linkesch +22 more
2003Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis20 citations
Semantic Scholar
Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: An interim analysis
H. Ludwig, E. Tóthová, R. Hájek, J. Drach +13 more
200519 citations
Semantic Scholar
Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT).
E. Woell, R. Greil, W. Eisterer, M. Fridrik +5 more
2016Journal of Clinical Oncology18 citations
Semantic Scholar
Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients.
F. Fitzal, M. Filipits, C. Fesl, M. Rudas +15 more
201418 citations
Semantic Scholar
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
E. Wöll, R. Greil, W. Eisterer, Oliver E. Bechter +8 more
2011Anticancer Research18 citations
Semantic Scholar
A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors
C. Dittrich, M. Fridrik, R. Koenigsberg, C. Lee +3 more
2014Investigational new drugs17 citations Open access
Semantic Scholar
Three-dimensional ultrasound to assess the response to treatment in gynecological malignancies.
C. Yaman, M. Fridrik
2005Gynecologic Oncology17 citations
Semantic Scholar
Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial
R. Greil, P. Obrtlíková, L. Smolej, T. Kozák +26 more
201414 citations
Semantic Scholar
Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer
B. Mlineritsch, Renate Schabel-Moser, J. Andel, M. Fridrik +5 more
2009Oncology Research and Treatment13 citations
Semantic Scholar
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer: First results of a multicenter phase II trial (AGMT Gastric- 2
E. Woell, R. Greil, W. Eisterer, M. Fridrik +5 more
200813 citations
Semantic Scholar
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.
E. Wöll, J. Thaler, F. Keil, B. Gruenberger +8 more
2017Anticancer Research12 citations Open access
Semantic Scholar
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
M. Pircher, B. Mlineritsch, M. Fridrik, C. Dittrich +10 more
2015Anticancer Research12 citations
Semantic Scholar
Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized Trial
M. Fridrik, A. Petzer, F. Keil, W. Willenbacher +7 more
201112 citations
Semantic Scholar
A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients
G. Piringer, M. Fridrik, Alfred Fridrik, A. Leiherer +9 more
2018Supportive Care in Cancer11 citations
Semantic Scholar
Erratum to: Iron metabolism and iron supplementation in cancer patients
H. Ludwig, R. Evstatiev, G. Kornek, M. Aapro +13 more
2015Wiener Klinische Wochenschrift11 citations Open access
Semantic Scholar
Monitoring of remission status by fluorescence in situ hybridisation in chronic myeloid leukaemia patients treated with interferon-alpha.
H. Duba, S. Peter, Wolfgang Hilbe, T. Fluckinger +4 more
1999International Journal of Oncology9 citations
Semantic Scholar
AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma)
B. Kiesewetter, R. Greil, W. Willenbacher, P. Neumeister +2 more
20158 citations
Semantic Scholar
Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results
A. Egle, M. Steurer, F. Gassner, R. Geisberger +7 more
20138 citations
Semantic Scholar
A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results
A. Egle, M. Steurer, F. Gassner, R. Geisberger +6 more
20118 citations
Semantic Scholar
Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG‐14
C. Tausch, G. Steger, A. Haid, R. Jakesz +6 more
2011The Breast Journal7 citations Open access
Semantic Scholar
Retreatment with Alemtuzumab after a First, Successful Alemtuzumab Treatment in B-CLL.
M. Fiegl, F. Falkner, A. Falkner, N. Zojer +9 more
20077 citations
Semantic Scholar
[Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
R. Pichler, W. Maschek, M. Hatzl-Griesenhofer, H. Huber +3 more
2000NuclearMedicine7 citations
Semantic Scholar
Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study
U. Jaeger, M. Trněný, Helen Melzer, M. Praxmarer +18 more
20136 citations
Semantic Scholar
5.28 Combining Fludarabine and Rituximab With Escalating Doses of Lenalidomide in Untreated Chronic Lymphocytic Leukemia: The REVLIRIT CLL5 AGMT Phase 1/2 Study—Results from Clinical and Exploratory Analyses of Induction
A. Egle, M. Steurer, F. Gassner, R. Geisberger +6 more
20116 citations
Semantic Scholar
Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial
H. Ludwig, E. Gunsilius, M. Fridrik, R. Greil +7 more
20165 citations
Semantic Scholar
Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis
S. Burgstaller, M. Fridrik, Sabine Hojas, T. Kühr +8 more
2013Wiener Klinische Wochenschrift5 citations
Semantic Scholar
Dose-dense therapy improves survival in aggressive non-Hodgkin’s lymphoma
M. Fridrik, H. Hausmaninger, A. Lang, J. Drach +7 more
2010Annals of Hematology5 citations Open access
Semantic Scholar
Long-term results of dose density therapy in patients with aggressive lymphoma
M. Fridrik, H. Hausmaninger, W. Linkesch, R. Greil +5 more
2005Annals of Hematology5 citations
Semantic Scholar
Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study
A. Egle, L. Weiss, T. Melchardt, E. Gunsilius +6 more
20104 citations
Semantic Scholar
First annual report of the Austrian CML registry
S. Schmidt, D. Wolf, J. Thaler, S. Burgstaller +16 more
2010Wiener Klinische Wochenschrift4 citations
Semantic Scholar
Klinische Wertigkeit der Befunde von FDG-PET mittels Koinzidenz-Gamma-kamera beim Staging and Restaging maligner Lymphome -ein Vergleich zu konventioneller Diagnostik
R. Pichler, W. Maschek, M. Hatzl-Griesenhofer, H. Huber +3 more
20004 citations
Semantic Scholar
Prospective screening for human epidermal growth factor receptor 2 (HER2) positivity in patients with inoperable locally advanced or metastatic gastric or gastro-esophageal junction cancer. AGMT gastric-5.
E. Woell, P. Regitnig, W. Eisterer, J. Thaler +8 more
20143 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Greil×33
Invite
R. Greil — researcher profile on SciRah
J. Thaler×17
Invite
J. Thaler — researcher profile on SciRah
A. Lang×14
Invite
A. Lang — researcher profile on SciRah
M. Gnant×12
Invite
M. Gnant — researcher profile on SciRah

×10

Invite

R. Jakesz — researcher profile on SciRah

H. Hausmaninger×9

Invite

H. Hausmaninger — researcher profile on SciRah

B. Mlineritsch×8

Invite

B. Mlineritsch — researcher profile on SciRah

S. Burgstaller×8

Invite

S. Burgstaller — researcher profile on SciRah

Invite

W. Eisterer — researcher profile on SciRah

Invite

H. Samonigg — researcher profile on SciRah

Invite

G. Steger — researcher profile on SciRah

Invite

M. Steurer — researcher profile on SciRah